Eisai

Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules

Monday, May 18, 2020 - 5:33am

Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.

Key Points: 
  • Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.
  • The compounding amount of 'teprenone' was increased to 150mg / day for New Selbelle Premium from 112.5 mg / day for the conventional product.
  • In addition, New Selbelle Premium contains two natural extracts that revitalize stomach functions and digestive enzymes that help to digest fat.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

Thursday, May 14, 2020 - 1:22am

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Key Points: 
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer.
  • There is no guarantee that any investigational compounds and investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Eisai to Voluntarily Withdraw BELVIQ®/BELVIQ XR® in the U.S.

Thursday, February 13, 2020 - 8:38pm

WOODCLIFF LAKE, N.J., Feb. 13, 2020 /PRNewswire/ -- Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ(lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S.

Key Points: 
  • WOODCLIFF LAKE, N.J., Feb. 13, 2020 /PRNewswire/ -- Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ(lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S.
  • At the time of marketing approval from BELVIQ, the FDA required Eisai to perform a long-term trial evaluating the cardiovascular effects associated with the use of the drug.
  • In this trial, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo.
  • However, based on the change in FDA's risk-benefit assessment and as requested by the Agency, Eisai has agreed to voluntarily withdraw the products from the U.S. market.

Global Lennox-Gastaut Syndrome Treatment Market 2019-2023|Growing Awareness of LGS to Boost Growth | Technavio

Wednesday, February 5, 2020 - 1:15am

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR31048

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR31048
    Lennox-Gastaut Syndrome Treatment Market 2019-2023: Scope
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our lennox-gastaut syndrome treatment market report covers the following areas:
    This study identifies advances in surgical treatments as one of the prime reasons driving the lennox-gastaut syndrome treatment market growth during the next few years.
  • Lennox-Gastaut Syndrome Treatment Market 2019-2023: Vendor Analysis
    We provide a detailed analysis of around 25 vendors operating in the lennox-gastaut syndrome treatment market, including some of the vendors such as Eisai Co., Ltd., GlaxoSmithKline plc., H. Lundbeck A/S, Johnson & Johnson Services, Inc. and Supernus Pharmaceuticals, Inc..Backed with competitive intelligence and benchmarking, our research reports on the lennox-gastaut syndrome treatment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Lennox-Gastaut Syndrome Treatment Market 2019-2023: Key Highlights
    Technavio is a leading global technology research and advisory company.

Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium

Tuesday, January 21, 2020 - 10:27pm

WOODCLIFF LAKE, N.J., Jan. 21, 2020 /PRNewswire/ --Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25.

Key Points: 
  • WOODCLIFF LAKE, N.J., Jan. 21, 2020 /PRNewswire/ --Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25.
  • Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA treated patients.
  • Fistula Formation and Gastrointestinal Perforation.Of the 799 patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and HCC, fistula or gastrointestinal perforation occurred in 2%.
  • LENVIMA is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/eisai-to-present-latest-data-on-...

Athersys Names Ivor Macleod Chief Financial Officer

Wednesday, January 15, 2020 - 11:00am

CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the addition of Mr. Ivor Macleod, CPA, MBA, a highly experienced pharmaceutical executive, to the Athersys leadership team.

Key Points: 
  • CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the addition of Mr. Ivor Macleod, CPA, MBA, a highly experienced pharmaceutical executive, to the Athersys leadership team.
  • Mr. Macleod has been appointed Chief Financial Officer, effective as of January 31, 2020, to help plan and execute the financial strategy through potential product commercialization.
  • Prior to joining Athersys, Mr. Macleod served as Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. subsidiary of the Japanese company, Eisai Ltd, where he led the overall financial strategy and performance of the company, including several strategic projects to both commercialize and optimize performance of portfolio products.
  • We are truly excited to have Ivor Macleod join the Athersys team.

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

Tuesday, December 24, 2019 - 6:00am

(Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib, an investigational, oral, selective JAK1 inhibitor, in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA).

Key Points: 
  • (Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib, an investigational, oral, selective JAK1 inhibitor, in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA).
  • Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications.
  • Filgotinib is pending regulatory approval in Japan, Europe and the United States, based on global Phase 3 trials evaluating its efficacy and tolerability.
  • All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

CancerCare® to Provide Vital Support for Cancer Patients Impacted by the California Wildfires

Monday, December 16, 2019 - 3:00pm

As a leading national nonprofit organization serving people affected by cancer, CancerCareis well aware of the disruption natural disasters can cause to cancer patients and their families.

Key Points: 
  • As a leading national nonprofit organization serving people affected by cancer, CancerCareis well aware of the disruption natural disasters can cause to cancer patients and their families.
  • In 2017, the organization raised almost $665,000 in direct financial assistance for people with cancer who had been impacted by Hurricanes Harvey, Irma, Jose and Maria.
  • As always, CancerCare stands ready to help cancer patients offset the financial burden of a cancer diagnosis.
  • CancerCare thanks Eisai USA Foundation, Inc. for its generous support that has made possible CancerCare's California Wildfires Patient Assistance Program.

Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting

Monday, December 9, 2019 - 1:06pm

WOODCLIFF LAKE, N.J., Dec. 9, 2019 /PRNewswire/ -- Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore.

Key Points: 
  • WOODCLIFF LAKE, N.J., Dec. 9, 2019 /PRNewswire/ -- Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore.
  • Of Eisai's 38 scientific posters about FYCOMPA, 23 included convulsive seizure freedom data underscoring Eisai's continued commitment to helping as many patients as possible achieve the ultimate goal of seizure freedom.
  • "This data provides important insights that we hope will help health care professionals as we work collectively toward the ultimate goal of seizure freedom."
  • Partial-onset seizures are the most common type of seizure seen in people with epilepsy, accounting for 60 percent of all seizures.

Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conference

Monday, December 2, 2019 - 3:18pm

Eisai will book all sales for BAN2401 following marketing approval and launch, and profits will be equally shared between the companies.

Key Points: 
  • Eisai will book all sales for BAN2401 following marketing approval and launch, and profits will be equally shared between the companies.
  • Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease.
  • BAN2401 is an investigational humanized monoclonal antibody for Alzheimer's disease that is the result of a strategic research alliance between Eisai and BioArctic.
  • Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease.